These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Tsai G; Lane HY; Yang P; Chong MY; Lange N Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571 [TBL] [Abstract][Full Text] [Related]
9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
10. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials]. Semba J Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198 [TBL] [Abstract][Full Text] [Related]
11. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission. Leonetti M; Desvignes C; Bougault I; Souilhac J; Oury-Donat F; Steinberg R Neuroscience; 2006; 137(2):555-64. PubMed ID: 16289893 [TBL] [Abstract][Full Text] [Related]
12. Glutamatergic animal models of schizophrenia. Moghaddam B; Jackson ME Ann N Y Acad Sci; 2003 Nov; 1003():131-7. PubMed ID: 14684441 [TBL] [Abstract][Full Text] [Related]
13. Changing concepts in the neurochemistry of schizophrenia. Tamminga CA; Frost DO Am J Psychiatry; 2001 Sep; 158(9):1365-6. PubMed ID: 11532717 [No Abstract] [Full Text] [Related]
15. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Heresco-Levy U; Silipo G; Javitt DC Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096 [TBL] [Abstract][Full Text] [Related]
16. [Mechanism of the modulating effect of met-enkephalin on glutamatergic synaptic transmission]. Kuznetsov VI; Golukhin OV Dokl Akad Nauk SSSR; 1985; 282(2):456-9. PubMed ID: 2861979 [No Abstract] [Full Text] [Related]
17. [Current status of biochemical hypotheses in the pathogenesis of schizophrenia]. Kornhuber J; Weller M Nervenarzt; 1994 Nov; 65(11):741-54. PubMed ID: 7816150 [TBL] [Abstract][Full Text] [Related]
18. NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Bekkers JM; Stevens CF Nature; 1989 Sep; 341(6239):230-3. PubMed ID: 2571090 [TBL] [Abstract][Full Text] [Related]
19. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. McBain CJ; Kleckner NW; Wyrick S; Dingledine R Mol Pharmacol; 1989 Oct; 36(4):556-65. PubMed ID: 2554111 [TBL] [Abstract][Full Text] [Related]
20. [Hypoglutamatergic hypothesis of schizophrenia: evidence from genetic studies]. Itokawa M; Yoshikawa T Seishin Shinkeigaku Zasshi; 2003; 105(11):1349-62. PubMed ID: 14758783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]